Economic Evaluation alongside the Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen in Extreme Preterm Babies
Rattachement africain : gb, qa, ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Objective To conduct an economic evaluation alongside the placebo-controlled trial of selective early treatment of patent ductus arteriosus with ibuprofen in extreme preterm babies. Design Within-trial economic evaluation alongside a multicentre, randomized, masked, placebo-controlled trial. Setting Thirty-two UK tertiary neonatal intensive care units. Sample Babies born between 23 +0 to 28 +6 weeks’ gestation, less than 72 hours old and confirmed by echocardiography to have a large PDA. Methods A cost-effectiveness analysis was conducted from the National Health Service (NHS) and NHS and Personal Social Services perspectives. Nonparametric bootstrapping was used to estimate incremental costs and outcomes which were reported as cost-effectiveness acceptability curves. Main outcome measures Cost per additional major outcome averted. Results Ibuprofen is less costly with an average cost per participant of £126,465 compared to £133,260 (-£6,808 (95% CI: £-17,154 to £3,537) for placebo. But it is less effective in terms of major outcomes averted with an absolute effect difference of 0.054 (95% CI: -0.014 to 0.121). The differences in mean cost were mainly attributable to the costs of high dependency care (£2,345, 95% CI -£3,435 to £8,126) and intensive care (£6,718, 95% CI - £12,627 to £26,063) which were higher in the placebo arm. The incremental cost-effectiveness ratio was estimated at £126,846 for an additional case of death, or severe or moderate bronchopulmonary dysplasia avoided by 36 weeks of post-menstrual age. Conclusions Based on the evidence from this trial, ibuprofen would not be recommended. There is insufficient evidence to suggest that any of the observed detrimental impact on effectiveness would be outweighed by the opportunity cost associated of any saving in costs.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Economic Evaluation alongside the Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen in Extreme Preterm Babies
- Date Crossref
- 24/06/2025
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Birmingham City University pays non établi dans la noticeUniversité ou école supérieure
-
University of Birmingham Department of Applied Health Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Durham University Department of Engineering pays non établi dans la noticeUniversité ou école supérieure
-
Sidra Medical and Research Center pays non établi dans la noticeÉtablissement de santé
-
University of Liverpool pays non établi dans la noticeUniversité ou école supérieure
-
Liverpool Womens NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
University of Oxford Clinical Trials Unit pays non établi dans la noticeUniversité ou école supérieure
-
University of Leicester Department of Health Science pays non établi dans la noticeUniversité ou école supérieure
-
NIHR Leicester Biomedical Research Centre pays non établi dans la noticeStructure de recherche
-
Rosie Hospital pays non établi dans la noticeÉtablissement de santé
-
Cambridge University Hospitals NHS Foundation Trust pays non établi dans la noticeOrganisme public
-
University Hospital Foundation Rosie Hospital pays non établi dans la noticeOrganisation à but non lucratif
Birmingham City University, Department of Applied Health Sciences — University of Birmingham et Department of Engineering — Durham University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.